Physician profile
Manuel E Alva
NPI 1255405452
$2,005.70
in general payments reported to CMS, 2019-2025
15 companies · $534 in 2025
The $534 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.60 · 2020: $15.00 · 2021: $25.68 · 2022: $186 · 2023: $426 · 2024: $764 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,723.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $474.29 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $416.67 | 2022-2025 | Stelara, Tremfya, Remicade |
| Abbvie INC. | $256.70 | 2024-2025 | |
| Boston Scientific Corporation | $190.51 | 2023-2025 | Bodyguardian, Cds - Mct/Cem Monitoring |
| Pfizer INC. | $143.18 | 2024-2025 | |
| Gilead Sciences, INC. | $135.83 | 2023-2025 | Trodelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.87 | 2024 | Xifaxan, Plenvu |
| Ardelyx, INC. | $65.18 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $60.14 | 2023-2024 | Ocaliva |
| Celgene Corporation | $52.85 | 2023-2024 | Zeposia |
| Abiomed | $41.90 | 2024 | Impella |
| Merck Sharp & Dohme LLC | $38.25 | 2024 | Dificid |
| Mauna Kea Technologies, INC. | $25.68 | 2021 | |
| Qol Medical, LLC | $15.59 | 2019 | |
| Echosens North America, INC. | $15.06 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Alva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.